Health and Human Services Secretary Xavier Becerra is the special guest for this bonus episode of KHN’s “What the Health?” podcast. He and host Julie Rovner discuss a breadth of topics the secretary oversees, including covid-19, prescription drug prices, Medicare, Medicaid and the Affordable Care Act.
Food insecurity soared during the pandemic, including among unauthorized immigrants, who are not eligible for federally funded food stamps. California’s Democratic lawmakers want to expand the benefit to that population, but opponents cite the massive ongoing cost to the state.
A group of New York senior living facilities offer teens from 10 underserved schools the chance to volunteer and get free training for entry-level health jobs, career coaching and assistance on college prep.
It could take years for follow-up studies to prove Aduhelm slows the disease — or doesn’t. Meanwhile, its maker will profit.
Thousands of schools have spent millions of federal covid relief dollars snapping up air cleaning technology that claims to inactivate covid-19. But the devices fall into a regulatory gap.
The president, one of the last of a disappearing group of politicians who sought moderate compromises on abortion policy, is frustrating supporters. They wanted faster changes in federal rules. But abortion opponents — including Catholic bishops— are also taking him to task.
The potential benefits of Aduhelm are small, its effectiveness is not certain, and even the FDA Thursday shifted its guidance on who should get the drug. But physicians are dealing with an onslaught of interest from patients and their families, and figuring out which patients are best positioned to be helped by the drug will be difficult.
Policies mandating company approval before talking publicly about conditions in hospitals have been a source of conflict over the past year, as physicians, nurses and other health workers have been disciplined for speaking or posting about what they view as dangerous covid-19 safety precautions. The appeals court’s decision could mean that hospitals — and other employers — will need to revise their policies.
The pharmaceutical industry argues that large profits are needed to fund extensive research and innovation. But Democrats on the House Oversight and Reform Committee, seeking to bolster their effort to let Medicare negotiate drug prices, say major drug companies plow more of their billions in earnings back into propping up their stock and enriching executives and shareholders.
Your dutiful columnist tried to make use of a federal “transparency” rule to compare the prices of common medical procedures in two California health care systems. It was a futile exercise.
